Products
Meropenem is commercially available as a powder for solution for injection/infusion (Meronem, generic). It has been approved in many countries since 1995. The antibiotic is also combined with the beta-lactamase inhibitor vaborbactam.
Structure and properties
Meropenem (C17H25N3O5S, Mr = 383.5 g/mol) is present in drugs as meropenem trihydrate, a white to slightly yellowish crystalline powder that is practically insoluble in water. It belongs to the beta-lactam antibiotics and the carbapenems.
Effects
Meropenem (ATC J01DH02) has bactericidal properties against Gram-positive and Gram-negative pathogens. The effects are based on binding to penicillin-binding proteins and inhibition of bacterial cell wall synthesis. Meropenem is stable to many beta-lactamases and has a half-life of approximately one hour.
Indications
For treatment of bacterial infectious diseases with susceptible pathogens.
Dosage
According to the SmPC. The drug is administered as an intravenous injection or infusion.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Meropenem is subject to active secretion at the kidney. Corresponding drug interactions are possible, for example with probenecid. An interaction with valproic acid has also been described.
Adverse effects
The most common potential adverse effects include local injection site reactions such as inflammation and pain, headache, rash, pruritus, thrombocythemia, nausea, vomiting, and diarrhea.
